Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II Trial of Vincristine + Irinotecan With or Without Temozolomide in Relapsed/Refractory Rhabdomyosarcoma
2010-023135-42Phase 2Completed
- Sponsor
- Centre Oscar Lambret
- Start
- May 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vincristine, irinotecan and temozolomide in rhabdomyosarcoma (RMS) (2 arms), sponsored by Centre Oscar Lambret. Primary endpoint: Objective tumor response. Started May 2011; status: completed.
02
Drugs
vincristineirinotecantemozolomide
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on 2010-023135-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023135-42.